Definitive insights to shape healthier futures

Advanced genetic testing solutions can identify conditions that can affect newborns and their long-term health or survival. These solutions can help labs in their efforts to drive early detection of genetic health risks in an efficient manner, enabling children to reach their full potential.

 

Applied Biosystems TaqMan SCID/SMA Plus Assay and TaqMan SCID/SMA Assay enable labs to analyze severe combined immunodeficiency syndrome (SCID) and spinal muscular atrophy (SMA) in newborns. 

 

Shape the future of reproductive health by strengthening newborn screening capabilities of your lab.

Customer & solutions overview

A high-quality multiplex assay

The TaqMan SCID/SMA Plus Assay is robust and optimized for high specificity to detect homozygous deletion of SMN1. It provides flexibility for SCID detection aligned with labs' approach with assay evaluating TREC and KREC, or TREC only.

Rapid and robust workflow for SCID/SMA detection

Our latest poster puts emphasis on the highly specific and sensitive multiplex assay for SCID and SMA testing with a robust workflow.

A reliable assay from sample to insight for optimized DBS workflow

With less than two hours turnaround time (TAT) from punch-to-answer, a dried blood sample (DBS) workflow to further decrease hands on time and increase throughput for SCID/SMA testing.

SCID/ SMA detection using DBS with less hands-on time

Optimized assay with workflow that’s adaptable to standard laboratory equipment, and compatible across multiple QuantStudio platforms. Work efficiency equals cost efficiency.

Why choose TaqMan Assays

Backed by more than 40,000 publications, TaqMan Assays offer specificity, sensitivity, and reproducibility with guaranteed performance.

Real-Time PCR and Digital PCR Instruments Support Center

One resource for all of your real-time PCR and digital PCR instrument support needs.


TaqMan SCID/SMA Plus Assay



 

QuantStudio 6 and 7 Flex Real-Time PCR Systems Software